- Home
- IQI vs CELC Comparison
IQI vs CELC Comparison
Compare IQI & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQI
- CELC
- Stock Information
- Founded
- IQI 1992
- CELC 2011
- Country
- IQI United States
- CELC United States
- Employees
- IQI N/A
- CELC N/A
- Industry
- IQI Finance Companies
- CELC Medical Specialities
- Sector
- IQI Finance
- CELC Health Care
- Exchange
- IQI Nasdaq
- CELC Nasdaq
- Market Cap
- IQI 527.3M
- CELC 594.7M
- IPO Year
- IQI N/A
- CELC 2017
- Fundamental
- Price
- IQI $9.99
- CELC $12.66
- Analyst Decision
- IQI
- CELC Strong Buy
- Analyst Count
- IQI 0
- CELC 6
- Target Price
- IQI N/A
- CELC $29.17
- AVG Volume (30 Days)
- IQI 162.1K
- CELC 257.7K
- Earning Date
- IQI 01-01-0001
- CELC 11-14-2024
- Dividend Yield
- IQI 4.61%
- CELC N/A
- EPS Growth
- IQI N/A
- CELC N/A
- EPS
- IQI N/A
- CELC N/A
- Revenue
- IQI N/A
- CELC N/A
- Revenue This Year
- IQI N/A
- CELC N/A
- Revenue Next Year
- IQI N/A
- CELC N/A
- P/E Ratio
- IQI N/A
- CELC N/A
- Revenue Growth
- IQI N/A
- CELC N/A
- 52 Week Low
- IQI $8.05
- CELC $11.51
- 52 Week High
- IQI $10.00
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- IQI 40.85
- CELC 28.22
- Support Level
- IQI $10.01
- CELC $15.33
- Resistance Level
- IQI $10.13
- CELC $16.14
- Average True Range (ATR)
- IQI 0.08
- CELC 0.97
- MACD
- IQI 0.01
- CELC -0.28
- Stochastic Oscillator
- IQI 38.33
- CELC 22.85
About IQI Invesco Quality Municipal Income Trust
Invesco Quality Municipal Income Trust is a diversified, closed-end management investment company. Its investment objective is to provide current income which is exempt from federal income tax.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.